Analytical Data
-
基因名
MMD
- Application
-
别名
Monocyte to macrophage differentiation factor. Progestin and adipoQ receptor family member 11. Progestin and adipoQ receptor family member XI
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q15546
-
表达区间
1-238 aa
-
氨基酸序列
MRFKNRFQRFMNHRAPANGRYKPTCYEHAANCYTHAFLIVPAIVGSALLHRLSDDCWEKITAWIYGMGLCALFIVSTVFHIVSWKKSHLRTVEHCFHMCDRMVIYFFIAASYAPWLNLRELGPLASHMRWFIWLMAAGGTIYVFLYHEKYKVVELFFYLTMGFSPALVVTSMNNTDGLQELACGGLIYCLGVVFFKSDGIIPFAHAIWHLFVATAAAVHYYAIWKYLYRSPTDFMRHL
-
分子量
54.1 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MMD (Molecular Mechanism of Disease) recombinant proteins have emerged as a significant focus in biomedical research due to their potential to elucidate disease mechanisms and develop novel therapeutic strategies. The increasing prevalence of various diseases, including cancer, neurodegenerative disorders, and metabolic syndromes, has driven the need for a deeper understanding of molecular pathways involved in these conditions. Recombinant proteins, produced through genetic engineering techniques, allow for the precise study of specific targets and interactions at a molecular level. This approach has revolutionized drug discovery by enabling the design of targeted therapies and biologics. Furthermore, MMD research often involves the use of advanced technologies such as CRISPR and high-throughput screening, which facilitate the identification of functionally relevant pathways and potential drug candidates. The ability to produce large quantities of pure proteins has also advanced vaccine development and the creation of biomarker-based diagnostic tools. As a result, MMD recombinant proteins are not only pivotal for basic research but also hold promise for translational applications, bridging the gap between laboratory findings and clinical solutions. Understanding their role in disease will be crucial for future innovations in patient care and personalized medicine.
